Skip to content
Jump to main navigation and login
Nav view search
About the Bing Center
Bing Center Staff
Directions / Find Us
Bing Center News
Bing Center Spotlight
Waldenstrom's Macroglobulinemia Clinic
WM Clinical Trials Group
Related Web Links
How To Help
You are here:
Latest Bing Center News
US FDA Approves New Imbruvica/Ibrutinib Formulation
On February 16, 2018, Imbruvica (ibrutinib) was approved by the US FDA in multiple strengths as a 140, 280, 420, and 460 mg tablet. The new formulations are now commercially available, and the original 140 mg capsule will no longer be available after May 15, 2018. Please see the full Prescribing Information (link is external) for indications, dosage and usage.
Online WM Workshop - Progress in the Treatment of WM
On Wednesday, June 27th, 2018 from 1:30PM – 2:30PM EST, Dr. Jorge Castillo of Dana-Farber Cancer Institute and Dr. Morie Gertz of Mayo Clinic will engage in a discussion on “Progress in the Treatment of Waldenstrom’s Macroglobulinemia (WM).” The program is free, but you must register to participate. https://www.iwmf.com/news-and-events/news/sign-free-iwmf-cancercare-onlinephone-wm-workshop-0
5th International Patient and Physician Summit on WM
Dear Friends: It is with great pleasure to invite you to the 5th International Patient and Physician Summit on Waldenstrom’s Macroglobulinemia (WM). The Summit will take place on October 13-14, 2018, at the New York Marriott Downtown Hotel and Conference Center, situated in Lower Manhattan next to the Freedom Tower.
59th Annual ASH Meeting - Bing Center Poster Presentations
The 59th Annual ASH meeting & exposition was held was held December 9-12, 2017 in Atlanta, GA. The following are the 16 posters presented by the Bing Center for Waldenstrom's Macroglobulinemia.
Special Presentation on Waldenstrom’s Macroglobulinemia Feb 3, 2017
Dr. Steven Treon, from the Dana-Farber Cancer Institute, is coming to Sarasota! Dr. Treon will be sharing an update on the current advances in clinical and laboratory research from the Bing Center for Waldenstrom’s Macroglobulinemia. Dr. Luis Chu, of Florida Cancer Specialists & Research Institute, Sarasota, will also be available for questions.
What’s New in the Treatment of Waldenstrom’s Macroglobulinemia (Webcast 10/4/2017)
This Webinar was held on October 4, 2017. The panel of experts: Jorge J. Castillo, MD: Bing Center for Waldenstrom’s Macroglobulinemia, Dana-Farber Cancer Institute, Assistant Professor, Harvard Medical School Jeffrey V. Matous, MD: Myeloma and Plasma Cell Diseases Program, Colorado Blood Cancer Institute Carl Harrington: President, IWMF - The International Waldenstrom’s Macroglobulinemia Foundation Sarah Kelly, MSW: Older Adult Program Coordinator, CancerCare
Atlanta, Georgia IWMF Support Group Lecture 12/9/2017
Date: December 9, 2017, 10:00 am-1:00 pm Location: Winship Cancer Institute of Emory University, 135 Clifton Road, Building C, 5th Floor, ROOM C5012, Atlanta, Georgia 30322 Topic: "Current Advances and Updates on Waldenstrom’s macroglobulinemia” presented by Dr. Steven Treon, Bing Center for WM, Dana Farber Cancer Institute
IWMF New England Support Group meeting 12/3/2017
IWMF New England Support Group meeting Date: December 3, 2017, 1:00 pm-3:30 pmLocation: Yawkey Building, 3rd FL, Conference Room 306 Topic: "Current Advances and Updates on Waldenstrom’s macroglobulinemia” presented by Dr. Jorge Castillo, Bing Center for WM, Dana Farber Cancer Institute.
Professor Treon Invited to Speak at the JSH Meeting in Tokyo, Japan on Waldenstrom’s Macroglobulinemia
Professor Treon speaking to delegates of the 79th Annual Meeting of the Japanese Society of Hematology. One hundred and fifty delegates to the 79th Annual Meeting of the Japanese Society of Hematology attended a workshop on Waldenstrom’s Macroglobulinemia, which featured Dr. Steve Treon, Professor of Medicine at Harvard Medical School and Director of the Bing Center for WM at the Dana Farber Cancer Institute.
Masterclass on Waldenstrom’s Macroglobulinemia for Hematology Doctors in Training in Ireland
Steve Treon with hematologists in training at the Masterclass on WM at the Haematology Association of Ireland, Belfast. Fifty hematologists in training attended the Masterclass on Waldenstrom’s Macroglobulinemia held as part of the Annual Meeting of the Hematology Association of Ireland (HAI) in Belfast. Dr. Steve Treon of the Bing Center for WM at the Dana Farber Cancer Institute gave a State of the Art Keynote lecture on Friday, October 13, 2017 entitled “Genomic and Treatment Advances in Waldenstrom’s Macroglobulinemia”.
The clinical trials listed below have been completed and are closed to enrollment:
Rituximab plus Fludarabine for patients with WM
Phase-2: Everolimus (RAD001) in Primary Therapy of Waldenstrom's Macroglobulinemia
Phase II Study of VELCADE (PS-341) in WM
Phase II Study of Thalidomide and Rituximab for patients with WM
Phase II Study of Simvastatin in WM
Phase II Study of Perifosine in Patients with Relapsed/Refractory WM
Phase II Study of Imatinib Mesylate (Gleevec) in Relapsed or Refractory WM
Phase II Study of Combination Therapy with bortezomib and rituximab in patients with relapsed/refractory Waldenstrom’s macroglobulinemia.
Phase II Study of CC-5013 (Lenalidomide , Revlimid(tm)) and rituximab in Waldenstrom's macroglobulinemia
Phase II Clinical Trial of Sildenafil Citrate in WM
Phase II Clinical Trial of RAD001 in relapsed/refractory lymphoma
Phase II Clinical Trial of combination therapy with bortezomib, dexamethasone, and rituximab in patients with WM
Extended Rituximab for patients with WM
Campath-1H for patients with relapsed and refractory WM
An Open Label, Multicenter Phase-2 Study of Single-Agent Enzastaurin HCl in Previously Treaed Waldenstrom's Macroglobulinemia or Multiple Myeloma